Sarah Leary, MD, is attending physician at Seattle Children’s Hospital and assistant professor in the Division of Pediatric Hematology/Oncology at the University of Washington School of Medicine. Her clinical and research focus is in the area of pediatric brain tumors.
Locally, she serves on the Tumor Tissue Subcommittee, the Research Review Committee and the Pediatric Scientific Review Committee. Nationally, she is study co-chair of the Pediatric Brain Tumor Consortium trial PBTC26 studying the feasibility of incorporating SAHA and retinoic acid into upfront therapy for infants with embryonal brain tumors. She is also a member of two Children’s Oncology Group study committees, a phase II trial of cilengitide in pediatric high-grade gliomas and a phase I trial of the AKT inhibitor, MK-2206. The goal of her clinical and translational research is to improve outcomes for brain tumor patients by developing biologically targeted therapeutics.